ZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc. (ZVSA) Stock Price Target 2026

The average analyst price target for ZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc. is $240, 239999900.0% above the current price. The one analyst covering it rates it Buy. The latest change came on Mar 12, 2024, when HC Wainwright & Co. lowered its price target on ZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc. from $480 to $240 and kept a Buy rating.

The Average Analyst Price Target for ZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc. is $240.

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$240Upside to Avg. PT+239999900.0%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for ZYVERSA THERAPEUTICS INC by ZyVersa Therapeutics, Inc. Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 26, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$12→$240
Mar 12, 2024	HC Wainwright & Co.	Ed Arce	PT Cut	Buy	$480→$240
Feb 29, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$480

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on ZyVersa Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates ZyVersa Therapeutics (NASDAQ:ZVSA) with a Buy and maintains $12 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on ZyVersa Therapeutics, Lowers Price Target to $12

HC Wainwright & Co. analyst Ed Arce maintains ZyVersa Therapeutics (NASDAQ:ZVSA) with a Buy and lowers the price target from $24 to $12.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ZyVersa Therapeutics, Maintains $24 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates ZyVersa Therapeutics (NASDAQ:ZVSA) with a Buy and maintains $24 price target.

Benzinga Newsdesk

Microcap Firm ZyVersa Therapeutics Shows Promise Despite IPO Volatility, Analyst Initiates With Buy

HC Wainwright initiated coverage on ZyVersa Therapeutics Inc (NASDAQ: ZVSA) with a Buy Rating and a

Vandana Singh

Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023

Benzinga Insights

PRO
HC Wainwright & Co. Initiates Coverage On ZyVersa Therapeutics with Buy Rating, Announces Price Target of $2.5

HC Wainwright & Co. analyst Ed Arce initiates coverage on ZyVersa Therapeutics (NASDAQ:ZVSA) with a Buy rating and announces Price Target of $2.5.

Benzinga Newsdesk